New radioactive therapy could delay chemotherapy for prostate cancer
NCT ID NCT05658003
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tests a radioactive drug called Lu-PSMA-617 against standard hormone therapy in 63 Chinese men with advanced prostate cancer that has stopped responding to treatment. The drug targets cancer cells with radiation. The goal is to see if it can delay cancer growth and the need for chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lutetium Lu 177 vipivotide tetraxetan (a radioactive drug that targets prostate cancer cells)
What this could lead to
If this works, it could offer a new treatment option that delays the need for chemotherapy in Chinese men with advanced prostate cancer.
What could go wrong
This is an early phase 2 study with only 63 participants, so results may not apply to all patients. The radioactive drug can cause side effects like dry mouth, fatigue, and low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Wuhan, Hubei, 430022, China
-
Novartis Investigative Site
Nanjing, Jiangsu, 210006, China
-
Novartis Investigative Site
Nanjing, Jiangsu, 210029, China
-
Novartis Investigative Site
Shenyang, Liaoning, 110011, China
-
Novartis Investigative Site
Xian, Shanxi, 710032, China
-
Novartis Investigative Site
Xian, Shanxi, 710061, China
-
Novartis Investigative Site
Chengdu, Sichuan, 610041, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310003, China
-
Novartis Investigative Site
Beijing, 100034, China
-
Novartis Investigative Site
Beijing, 100036, China
-
Novartis Investigative Site
Beijing, 100730, China
-
Novartis Investigative Site
Guangzhou, 510060, China
-
Novartis Investigative Site
Shanghai, 200025, China
-
Novartis Investigative Site
Shanghai, 200032, China
-
Novartis Investigative Site
Tianjin, 300308, China